The abstract is read at the publisher; the summary is JClub's.
In human non-small cell lung cancer, NAT10-modified RNA accumulates in NAT10+FOXP3+ Tregs, and Nat10 loss or NAT10 inhibition reduces the PD-1+ Treg/CD8+ T cell ratio.
- Why it matters: Tregs can blunt antitumor immunity during immune checkpoint blockade, so mechanisms that preserve Treg suppressive function in the tumor microenvironment are needed to improve anti-PD-1 responses.
- What they did: The study used genetic ablation of Nat10 in tumor-infiltrating Tregs and pharmacological inhibition of NAT10 expression, then assessed PD-1+ Treg/CD8+ T cell ratios, IFN-γ+ Tregs, and tumor progression.
- The result: NAT10 targeting increased IFN-γ+ Tregs, reduced Treg immunosuppressive activity, and inhibited tumor progression; combining anti-PD-1 with a NAT10 inhibitor further impaired TI Treg-mediated immunosuppression and improved tumor control.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.